Health Services Research & Development

Veterans Crisis Line Badge
Go to the ORD website
Go to the QUERI website

Publication Briefs



HSR&D Publication Briefs
view more Pub Briefs
 

Get RSS Feeds  

Study Compares Treat-to-Target Strategies to Tailored Approach for Statin Therapy


FINDINGS:

  • A simple Tailored Treatment strategy for statin therapy was more efficient and prevented substantially more coronary artery disease (CAD) morbidity and mortality than any of the currently recommended Treat-to-Target approaches.
  • The Tailored Treatment approach was predicted to save 520,000 more quality-adjusted life years among Americans aged 30-75 than the best NCEP III Treat-to-Target approach for every five years of treatment, even though fewer people were treated with high doses of statins.
  • The authors indicate that these results suggest that a Tailored Treatment approach to medicine can substantially improve care, while also reducing unnecessary treatment and costs. Thus, they recommend that given its potential to better tailor treatments to individual patients, the principles underlying a Tailored Treatment approach should be considered during deliberations about guidelines and performance measures.

BACKGROUND:
Statins are one of the most effective treatments in medicine, yet several controversies remain about their use. Although treating to lipid targets (Treat-to-Target) is widely recommended for coronary artery disease (CAD) prevention, some have advocated giving fixed doses of statins based upon an individual's estimated net benefit (Tailored Treatment). This study examined how a simple Tailored Treatment strategy compared with a Treat-to-Target strategy based on National Cholesterol Education Program (NCEP) III treatment recommendations. Investigators simulated the population-level impact of competing statin treatment guidelines using data from statin trials conducted from 1994 to 2009 and nationally-representative CAD risk factor data for Americans aged 30-75 with no history of heart attack. Outcomes were benefits achieved for a 5-year treatment period, e.g., quality-adjusted life-years (QALYs) gained.

LIMITATIONS:

  • Model assumptions were based on available clinical data, which included few individuals age 75 years and older, thus making recommendations for this group more uncertain.

AUTHOR/FUNDING INFORMATION:
This study was partly funded by VA/HSR&D's Quality Enhancement Research Initiative (QUERI). Drs. Hayward and Vijan are part of HSR&D's Center for Clinical Management Research in Ann Arbor, MI.


PubMed Logo Hayward R, Krumholz H, Zulman D, Timbie J, and Vijan S. Optimizing Statin Treatment for Primary Coronary Artery Disease Prevention. Annals of Internal Medicine January 19, 2010;152(2):69-77.

Related Briefs

» next 74 Heart Disease Briefs...


» next 139 Medication Briefs...


» next 23 Prevention Briefs...


What are HSR&D Publication Briefs?

HSR&D requires notification by HSR&D-funded investigators about all articles accepted for publication. These journal articles are reviewed by HSR&D and publication briefs or summaries are written for a select number of articles that are then forwarded to VHA Central Office leadership to keep them informed about important findings or information. Articles to be summarized are selected by HSR&D based on timeliness of the findings, interest of leadership, or potential impact on the organization. Publication briefs are written for only a small number of HSR&D published articles. Visit the HSR&D citations database for a complete listing of HSR&D articles and presentations.